Scarica l'app Stockscreener
9.90
2.06%
0.20
Precedente Chiudi:
$9.70
Aprire:
$9.73
Volume 24 ore:
1.02M
Relative Volume:
0.61
Capitalizzazione di mercato:
$983.10M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-4.9458
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
+6.91%
1M Prestazione:
+33.33%
6M Prestazione:
-1.69%
1 anno Prestazione:
-33.20%
Intervallo 1D:
$9.711
$10.15
Intervallo di 1 settimana:
$9.13
$10.17
Portata 52W:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.90 | 974.17M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Insider Sell: Eric Karas Sells 25,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock - Investing.com UK
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock - Investing.com
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals (SPRY) legal chief sells 3,355 shares in planned trade - Stock Titan
[144] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
SPRY Should I Buy - Intellectia AI
From Clinical To Market: Managing Pharma's Most Challenging Transition - Life Science Leader
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
(SPRY) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies - The Manila Times
SPRY Technical Analysis | Trend, Signals & Chart Patterns | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Food Allergy Market Expected to Experience Accelerated Growth - openPR.com
[Form 3] ARS Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Novartis, Roche, ARS Pharma, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Techno - Barchart.com
ARS Pharmaceuticals Hits Day High with 10.59% Surge in Stock Price - Markets Mojo
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential - Investing.com India
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald - Moomoo
Liquidity Mapping Around (SPRY) Price Events - Stock Traders Daily
Creek Drive Management Group LLC's ARS Pharmaceuticals Inc(SPRY) Holding History - GuruFocus
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - AOL.com
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
EX-99.1 - SEC.gov
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ars Pharmaceuticals Inc Azioni (SPRY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jun 12 '26 |
Sale |
10.00 |
25,000 |
250,000 |
12,176 |
| Fitzpatrick Alexander A | Chief Legal Officer |
Jun 12 '26 |
Sale |
10.00 |
3,355 |
33,550 |
90,910 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):